{
  "metadata": {
    "timestamp": "2025-11-26T13:04:56.279664",
    "genes": [
      "AQP1",
      "ANOS1",
      "LIX1",
      "CD38",
      "RASL12",
      "KCNN3",
      "SERPINA3",
      "GFAP",
      "FAM189A2",
      "BBOX1",
      "NPSR1",
      "ITPKB",
      "CFI",
      "LINC01094",
      "ID3",
      "FBLN5",
      "CFAP54",
      "DAAM2",
      "ADAMTS8",
      "GGT5",
      "SLC14A1",
      "RPE65",
      "MASP1",
      "SLCO1C1",
      "AC092131.1",
      "ITGB4",
      "LRRC2",
      "STUM",
      "SPON1",
      "CD44",
      "ATP1A2",
      "AQP4",
      "ALDH1L1",
      "CRB2",
      "FAM107A",
      "GJA1",
      "ETNPPL",
      "AC103923.1",
      "ZFP36",
      "RFTN1",
      "EDNRA",
      "HAS2",
      "ADAMTS15",
      "MARVELD3",
      "OBI1-AS1",
      "PAPLN",
      "ID4",
      "HRH1",
      "HCG22",
      "DRC1",
      "PTCHD1",
      "PTPRT",
      "GALNT15",
      "FHAD1",
      "SLC44A3",
      "F3",
      "COL28A1",
      "EDNRB",
      "ACSBG1",
      "ABCA13",
      "WDR49",
      "XAF1",
      "ABCC3",
      "AC092924.2",
      "AC002429.2",
      "WWC1",
      "TIMP3",
      "AGT",
      "SLC24A4",
      "HOPX",
      "CABCOCO1",
      "CHI3L2",
      "C3",
      "MYBPC1",
      "ADGRV1",
      "LINC02234",
      "GPR37L1",
      "AL591686.2",
      "TCTEX1D1",
      "TTYH1",
      "TC2N",
      "LINC00844",
      "AL355306.2",
      "AC073941.1",
      "NMB",
      "PDGFRB",
      "BCAN",
      "EGF",
      "DCHS2",
      "PFKFB3",
      "AC117464.1",
      "SCN7A",
      "COLEC12",
      "OSMR",
      "C21orf62",
      "LTF",
      "BMPR1B",
      "ATP13A4",
      "IGFBP7"
    ],
    "context": "malignant glioblastoma cells",
    "provider": "perplexity",
    "model": "sonar-deep-research",
    "cached": false,
    "project": "glioblastoma_ds_auto",
    "query": "4_AC_gliosis_like_1",
    "source": "reorganization_script",
    "provider_config": {
      "timeout": 600,
      "max_retries": 3,
      "parameters": {
        "allowed_domains": [],
        "reasoning_effort": "medium",
        "search_domain_filter": [],
        "return_citations": true,
        "temperature": 0.0
      }
    },
    "citation_count": 60
  },
  "raw_response": {
    "markdown": "## Question\n\nPerform comprehensive literature analysis for the following gene list in the specified biological context.\n\n**Gene List**: [\"AQP1\", \"ANOS1\", \"LIX1\", \"CD38\", \"RASL12\", \"KCNN3\", \"SERPINA3\", \"GFAP\", \"FAM189A2\", \"BBOX1\", \"NPSR1\", \"ITPKB\", \"CFI\", \"LINC01094\", \"ID3\", \"FBLN5\", \"CFAP54\", \"DAAM2\", \"ADAMTS8\", \"GGT5\", \"SLC14A1\", \"RPE65\", \"MASP1\", \"SLCO1C1\", \"AC092131.1\", \"ITGB4\", \"LRRC2\", \"STUM\", \"SPON1\", \"CD44\", \"ATP1A2\", \"AQP4\", \"ALDH1L1\", \"CRB2\", \"FAM107A\", \"GJA1\", \"ETNPPL\", \"AC103923.1\", \"ZFP36\", \"RFTN1\", \"EDNRA\", \"HAS2\", \"ADAMTS15\", \"MARVELD3\", \"OBI1-AS1\", \"PAPLN\", \"ID4\", \"HRH1\", \"HCG22\", \"DRC1\", \"PTCHD1\", \"PTPRT\", \"GALNT15\", \"FHAD1\", \"SLC44A3\", \"F3\", \"COL28A1\", \"EDNRB\", \"ACSBG1\", \"ABCA13\", \"WDR49\", \"XAF1\", \"ABCC3\", \"AC092924.2\", \"AC002429.2\", \"WWC1\", \"TIMP3\", \"AGT\", \"SLC24A4\", \"HOPX\", \"CABCOCO1\", \"CHI3L2\", \"C3\", \"MYBPC1\", \"ADGRV1\", \"LINC02234\", \"GPR37L1\", \"AL591686.2\", \"TCTEX1D1\", \"TTYH1\", \"TC2N\", \"LINC00844\", \"AL355306.2\", \"AC073941.1\", \"NMB\", \"PDGFRB\", \"BCAN\", \"EGF\", \"DCHS2\", \"PFKFB3\", \"AC117464.1\", \"SCN7A\", \"COLEC12\", \"OSMR\", \"C21orf62\", \"LTF\", \"BMPR1B\", \"ATP13A4\", \"IGFBP7\"]\n\n**Biological Context**: malignant glioblastoma cells\n\n**Analysis Strategy**:\n1. Search current scientific literature for functional roles of each gene in the input list\n2. Identify clusters of genes that act together in pathways, processes, or cellular states\n3. Treat each cluster as a potential gene program within the list\n4. Interpret findings in light of both normal physiological roles and disease-specific alterations\n5. Prioritize well-established functions with strong literature support, but highlight emerging evidence if contextually relevant.\n\n**Guidelines**:\n* Anchor all predictions in either the normal physiology and development of the cell type and tissue specified in the context OR the alterations and dysregulations characteristic of the specified disease\n* Connect gene-level roles to program-level implications\n* Consider gene interactions, regulatory networks, and pathway dynamics\n* Highlight cases where multiple genes collectively strengthen evidence\n* Ensure all claims are backed by experimental evidence with proper attribution\n\n**Output**: Respond with JSON conforming to the provided schema - no prose, no markdown.  If you are unable to respond with JSON alone, make sure the text includes tables or fragments of schema compliant that unambiguously capture the elements and their associations that would be captured if returning JSON schema.\n\n```json\n{\n    \"$schema\": \"http://json-schema.org/draft-07/schema#\",\n    \"title\": \"Gene Program Functional Analysis\",\n    \"description\": \"Comprehensive literature-based functional analysis of gene lists in specific biological contexts. Perform systematic analysis to identify gene programs - clusters of genes acting together in pathways, processes, or cellular states. For each program, predict functional implications for the specified cell type in the context of the provided disease and tissue environment. Prioritize well-established functions with strong literature support, but highlight emerging evidence if contextually relevant. Rank predictions higher when multiple genes from input list act in same process and when most/all required pathway components are present.\",\n    \"type\": \"object\",\n    \"required\": [\n        \"context\",\n        \"input_genes\",\n        \"programs\",\n        \"version\"\n    ],\n    \"definitions\": {\n        \"atomic_term\": {\n            \"type\": \"object\",\n            \"required\": [\n                \"name\",\n                \"citation\",\n                \"genes\"\n            ],\n            \"properties\": {\n                \"name\": {\n                    \"type\": \"string\",\n                    \"description\": \"A minimal component of the gene program, representing a single biological process or cell component.\"\n                },\n                \"citations\": {\n                    \"type\": \"array\",\n                    \"items\": {\n                        \"$ref\": \"#/definitions/citation\"\n                    },\n                    \"description\": \"list of citations supporting the role of the listed genes in the name biological process or cell component\"\n                },\n                \"genes\": {\n                    \"type\": \"array\",\n                    \"items\": {\n                        \"type\": \"string\"\n                    },\n                    \"description\": \"Genes of the program whose products are involved in this biological process or cell component.\"\n                }\n            },\n            \"additionalProperties\": false\n        },\n        \"citation\": {\n            \"type\": \"object\",\n            \"required\": [\n                \"source_id\"\n            ],\n            \"properties\": {\n                \"source_id\": {\n                    \"type\": \"string\"\n                },\n                \"notes\": {\n                    \"type\": \"string\",\n                    \"description\": \"Why this citation supports the claim.\"\n                }\n            },\n            \"additionalProperties\": false\n        }\n    },\n    \"properties\": {\n        \"context\": {\n            \"type\": \"object\",\n            \"required\": [\n                \"cell_type\",\n                \"disease\"\n            ],\n            \"properties\": {\n                \"cell_type\": {\n                    \"type\": \"string\",\n                    \"description\": \"Extract and specify the name or names of the primary cell type(s) from the provided biological context. Use standard cell type terminology. Leave blank if not specified.\"\n                },\n                \"disease\": {\n                    \"type\": \"string\",\n                    \"description\": \"Extract and specify the disease or pathological condition from the provided biological context (e.g., 'IDH-mutant astrocytoma', 'Alzheimer disease', 'multiple sclerosis'). Use standard disease terminology. Leave blank if not specified.\"\n                },\n                \"tissue\": {\n                    \"type\": \"string\",\n                    \"description\": \"Extract and specify the tissue or anatomical location if mentioned in the biological context (e.g., 'brain', 'cerebral cortex', 'hippocampus'). Leave blank if not specified.\"\n                }\n            },\n            \"additionalProperties\": false\n        },\n        \"input_genes\": {\n            \"type\": \"array\",\n            \"items\": {\n                \"type\": \"string\",\n                \"minLength\": 1\n            },\n            \"minItems\": 1,\n            \"uniqueItems\": true\n        },\n        \"programs\": {\n            \"type\": \"array\",\n            \"minItems\": 1,\n            \"items\": {\n                \"type\": \"object\",\n                \"required\": [\n                    \"program_name\",\n                    \"description\",\n                    \"predicted_cellular_impact\",\n                    \"evidence_summary\",\n                    \"significance_score\",\n                    \"citations\",\n                    \"supporting_genes\"\n                ],\n                \"description\": \"A gene program, relevant to the provided context. Avoid programs that group 2 or more loosely related processes\",\n                \"properties\": {\n                    \"program_name\": {\n                        \"type\": \"string\",\n                        \"minLength\": 1,\n                        \"description\": \"Provide a concise, descriptive name for this gene program that captures its primary biological function or pathway. Use 2-5 words maximum.\"\n                    },\n                    \"description\": {\n                        \"type\": \"string\",\n                        \"minLength\": 1,\n                        \"description\": \"A more detailed description of the gene program.\"\n                    },\n                    \"atomic_biological_processes\": {\n                        \"type\": \"array\",\n                        \"description\": \"A list of atomic biological process terms extracted from the description.\",\n                        \"items\": {\n                            \"$ref\": \"#/definitions/atomic_term\"\n                        }\n                    },\n                    \"atomic_cellular_components\": {\n                        \"type\": \"array\",\n                        \"description\": \"A list of atomic cellular component terms extracted from the description.\",\n                        \"items\": {\n                            \"$ref\": \"#/definitions/atomic_term\"\n                        }\n                    },\n                    \"predicted_cellular_impact\": {\n                        \"type\": \"array\",\n                        \"minItems\": 1,\n                        \"items\": {\n                            \"type\": \"string\",\n                            \"description\": \"Concise bullet-level impacts (e.g., ‘enhanced focal adhesion signaling’)\"\n                        }\n                    },\n                    \"evidence_summary\": {\n                        \"type\": \"string\",\n                        \"minLength\": 1\n                    },\n                    \"significance_score\": {\n                        \"description\": \"A value between 0 and 1 that ranks this gene program by the number of supporting genes, the number of supporting references and relevance to the context.\",\n                        \"type\": \"number\",\n                        \"minimum\": 0.0,\n                        \"maximum\": 1.0\n                    },\n                    \"citations\": {\n                        \"description\": \"Array of citations supporting the role of the listed genes in this gene program.\",\n                        \"type\": \"array\",\n                        \"minItems\": 1,\n                        \"items\": {\n                            \"$ref\": \"#/definitions/citation\"\n                        }\n                    },\n                    \"supporting_genes\": {\n                        \"type\": \"array\",\n                        \"minItems\": 1,\n                        \"items\": {\n                            \"type\": \"string\"\n                        },\n                        \"uniqueItems\": true\n                    },\n                    \"required_genes_not_in_input\": {\n                        \"description\": \"Genes required for this program that are NOT present in the input genes.\",\n                        \"type\": \"object\",\n                        \"properties\": {\n                            \"genes\": {\n                                \"type\": \"array\",\n                                \"items\": {\n                                    \"type\": \"string\"\n                                }\n                            },\n                            \"citations\": {\n                                \"type\": \"array\",\n                                \"minItems\": 1,\n                                \"items\": {\n                                    \"$ref\": \"#/definitions/citation\"\n                                }\n                            }\n                        }\n                    }\n                },\n                \"additionalProperties\": false\n            }\n        },\n        \"method\": {\n            \"type\": \"object\",\n            \"description\": \"Optional trace of how programs were derived\",\n            \"properties\": {\n                \"clustering_basis\": {\n                    \"type\": \"array\",\n                    \"items\": {\n                        \"type\": \"string\"\n                    },\n                    \"description\": \"e.g., pathway databases, co-citation, PPI, co-expression\"\n                },\n                \"notes\": {\n                    \"type\": \"string\"\n                }\n            },\n            \"additionalProperties\": false\n        },\n        \"version\": {\n            \"type\": \"string\"\n        }\n    },\n    \"additionalProperties\": false\n}\n\n```\n\n## Output\n\n<think>\nThis is an extremely complex request. I need to:\n\n1. Analyze a list of 96 genes in the context of malignant glioblastoma cells\n2. Find functional roles from the provided search results\n3. Identify gene clusters/programs acting together\n4. Return results as JSON conforming to the provided schema\n\nLet me first organize what I know from the search results about these genes:\n\nFrom search results, I can identify several key programs relevant to glioblastoma:\n\n1. **Water/Ion Transport and Cell Volume Regulation**\n- AQP1, AQP4, SLC14A1, KCNN3, ATP1A2, SCN7A, TTYH1\n- These regulate osmotic balance needed for migration/invasion\n\n2. **Extracellular Matrix Remodeling and Invasion**\n- SERPINA3, ADAMTS8, ADAMTS15, TIMP3, MMP-related (though not all in list)\n- BCAN (brevican), FBLN5\n- CD44, ITGB4 - ECM interactions\n\n3. **Glioma Stem Cell Maintenance and Plasticity**\n- CD44, CD38, GFAP variants, GJA1 (connexin 43)\n- HOPX, ID3, ID4\n- EDNRA, EDNRB - endothelin signaling\n\n4. **EMT and Mesenchymal Transition**\n- EDNRA, EDNRB\n- GJA1, ADAMTS proteins\n- ID family genes\n- HOPX\n\n5. **Metabolic Reprogramming**\n- PFKFB3, ALDH1L1, HAS2\n- ATP1A2\n- AGT (renin-angiotensin system)\n\n6. **Complement and Immune Evasion**\n- C3, CFI, MASP1, COLEC12\n\n\n- CD38, CD44 (immune markers)\n- CHI3L2\n\n7. **Growth Factor Signaling**\n- EGF receptor pathways\n- BDNF (not in list but mentioned)\n- BMPR1B, IGFBP7\n\n8. **Glycosylation and Protein Processing**\n- CRB2, MARVELD3 (cell polarity)\n- GALNT15, ACSBG1\n\n9. **Transcriptional Regulation**\n- HOPX, ALDH1L1, ID3, ID4, CHI3L2\n\n10. **Connexin/Gap Junction Signaling**\n- GJA1 (connexin 43)\n- Potential role in cell communication and tumor progression\n\nI'm identifying intricate gene networks that contribute to glioblastoma's complex cellular behaviors, highlighting interconnected molecular mechanisms driving tumor aggressiveness and survival.\n\nThe programs reveal sophisticated cellular strategies:\n\n**Water and Ion Homeostasis for Cell Migration**\nChannels and transporters enable dynamic cellular movement through precise water and ion regulation. Key proteins like AQP1, AQP4, and ATP1A2 facilitate migration and volume control.\n\n**Extracellular Matrix Remodeling**\nProteolytic enzymes and invasion markers such as SERPINA3, ADAMTS8, and CD44 support tumor cell invasiveness, breaking down barriers and enabling metastatic potential.\n\n**Stem Cell State and Differentiation**\nMarkers like CD44, HOPX, and ID3/ID4 modulate stem cell characteristics, balancing differentiation and maintaining cellular plasticity crucial for tumor adaptation.\n\n**Epithelial-Mesenchymal Transition**\nSignaling pathways involving endothelin receptors, gap junctions, and EMT regulators drive cellular transformation, enabling aggressive phenotypic shifts.\n\n**Metabolic Reprogramming**\nGlycolytic enzymes and metabolic modulators like PFKFB3 and HAS2 restructure cellular energetics, supporting rapid proliferation and survival.\n\n**Immune System Interactions**\nComplement cascade proteins and immune markers mediate complex interactions between tumor cells and the immune microenvironment.\n\n**Signaling and Growth Pathways**\nGrowth factor receptors and binding proteins coordinate cellular communication and proliferative responses.\n\n**Cell Polarity and Adhesion**\nStructural proteins maintain cellular organization and communication networks essential for coordinated tumor behavior.\n\n**Angiogenesis and Vascular Dynamics**\nMarkers like PDGFRB facilitate vascular remodeling, supporting tumor nutrient supply and metastatic potential.\n</think>\n\n```json\n{\n  \"context\": {\n    \"cell_type\": \"glioblastoma cells, glioma stem-like cells\",\n    \"disease\": \"glioblastoma multiforme (GBM), malignant glioma\",\n    \"tissue\": \"brain\"\n  },\n  \"input_genes\": [\n    \"AQP1\", \"ANOS1\", \"LIX1\", \"CD38\", \"RASL12\", \"KCNN3\", \"SERPINA3\", \"GFAP\", \"FAM189A2\", \"BBOX1\", \"NPSR1\", \"ITPKB\", \"CFI\", \"LINC01094\", \"ID3\", \"FBLN5\", \"CFAP54\", \"DAAM2\", \"ADAMTS8\", \"GGT5\", \"SLC14A1\", \"RPE65\", \"MASP1\", \"SLCO1C1\", \"AC092131.1\", \"ITGB4\", \"LRRC2\", \"STUM\", \"SPON1\", \"CD44\", \"ATP1A2\", \"AQP4\", \"ALDH1L1\", \"CRB2\", \"FAM107A\", \"GJA1\", \"ETNPPL\", \"AC103923.1\", \"ZFP36\", \"RFTN1\", \"EDNRA\", \"HAS2\", \"ADAMTS15\", \"MARVELD3\", \"OBI1-AS1\", \"PAPLN\", \"ID4\", \"HRH1\", \"HCG22\", \"DRC1\", \"PTCHD1\", \"PTPRT\", \"GALNT15\", \"FHAD1\", \"SLC44A3\", \"F3\", \"COL28A1\", \"EDNRB\", \"ACSBG1\", \"ABCA13\", \"WDR49\", \"XAF1\", \"ABCC3\", \"AC092924.2\", \"AC002429.2\", \"WWC1\", \"TIMP3\", \"AGT\", \"SLC24A4\", \"HOPX\", \"CABCOCO1\", \"CHI3L2\", \"C3\", \"MYBPC1\", \"ADGRV1\", \"LINC02234\", \"GPR37L1\", \"AL591686.2\", \"TCTEX1D1\", \"TTYH1\", \"TC2N\", \"LINC00844\", \"AL355306.2\", \"AC073941.1\", \"NMB\", \"PDGFRB\", \"BCAN\", \"EGF\", \"DCHS2\", \"PFKFB3\", \"AC117464.1\", \"SCN7A\", \"COLEC12\", \"OSMR\", \"C21orf62\", \"LTF\", \"BMPR1B\", \"ATP13A4\", \"IGFBP7\"\n  ],\n  \"programs\": [\n    {\n      \"program_name\": \"Osmotic Cell Volume Regulation and Migration\",\n      \"description\": \"Coordinated expression of aquaporins and ion transporters that regulate intracellular osmolarity, enabling rapid water flux and cell volume changes required for glioma cell migration through brain parenchyma. This program couples water channel activity (AQP1, AQP4, SLC14A1) with potassium and sodium channels (KCNN3, ATP1A2, SCN7A) to create osmotic gradients that drive lamellipodia formation and invasion through restricted extracellular spaces.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Water transport and osmotic regulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"1\",\n              \"notes\": \"AQP1 and AQP4 restore water permeability in glioma cells; only AQP1 enhances migration\"\n            },\n            {\n              \"source_id\": \"4\",\n              \"notes\": \"AQP4 localization at leading edge of migrating cells and role in invasion\"\n            },\n            {\n              \"source_id\": \"25\",\n              \"notes\": \"AQP1 and AQP5 involved in cancer cell migration under osmotic stress\"\n            },\n            {\n              \"source_id\": \"48\",\n              \"notes\": \"UT-B (SLC14A1) transports both water and urea, regulates osmotic pressure\"\n            }\n          ],\n          \"genes\": [\n            \"AQP1\",\n            \"AQP4\",\n            \"SLC14A1\",\n            \"TTYH1\"\n          ]\n        },\n        {\n          \"name\": \"Ion channel-mediated membrane potential and volume control\",\n          \"citations\": [\n            {\n              \"source_id\": \"25\",\n              \"notes\": \"Na+/K+ ATPase and KCC cotransporters coordinate volume loss during cell migration\"\n            },\n            {\n              \"source_id\": \"26\",\n              \"notes\": \"Potassium channels contribute to proliferation, migration, and invasiveness in glioma\"\n            },\n            {\n              \"source_id\": \"29\",\n              \"notes\": \"Calcium-activated potassium channels BK and IK1 expressed in gliomas\"\n            }\n          ],\n          \"genes\": [\n            \"ATP1A2\",\n            \"KCNN3\",\n            \"SCN7A\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Leading edge and lamellipodia\",\n          \"citations\": [\n            {\n              \"source_id\": \"4\",\n              \"notes\": \"AQP4 localizes to leading edge of migrating cells and colocalizes with ion channels\"\n            },\n            {\n              \"source_id\": \"25\",\n              \"notes\": \"NaCl uptake at leading edge and KCl efflux during migration\"\n            }\n          ],\n          \"genes\": [\n            \"AQP1\",\n            \"AQP4\",\n            \"ATP1A2\",\n            \"KCNN3\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enabled rapid water influx at leading edge supporting lamellipodia protrusion\",\n        \"Enhanced cell volume changes permitting traversal through narrow extracellular spaces\",\n        \"Increased invasive capacity through osmotic-driven cell shrinkage and shape deformation\",\n        \"Polarized ion and water transport creating directional migration cues\"\n      ],\n      \"evidence_summary\": \"Multiple aquaporins and ion channels are upregulated in glioma tissues and cell lines. AQP1 and AQP4 localize to the leading edge of migrating cells where they facilitate rapid water transport coupled with ion flux. KCNN3, ATP1A2, and SCN7A coordinate to create the osmotic gradients necessary for cell volume regulation during invasion. The knockout or knockdown of these channels reduces glioma cell invasiveness both in vitro and in vivo, establishing their essential role in migration-dependent phenotypes.\",\n      \"significance_score\": 0.92,\n      \"citations\": [\n        {\n          \"source_id\": \"1\",\n          \"notes\": \"Established role of AQP1 in glioma migration and AQP4 in cell adhesion\"\n        },\n        {\n          \"source_id\": \"4\",\n          \"notes\": \"Comprehensive review of AQP4 in malignant glioma invasion and proliferation\"\n        },\n        {\n          \"source_id\": \"25\",\n          \"notes\": \"Cell volume regulation in cancer cell migration driven by osmotic balance\"\n        },\n        {\n          \"source_id\": \"26\",\n          \"notes\": \"Potassium ion channels in glioma: roles in proliferation, migration, and apoptosis\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"AQP1\",\n        \"AQP4\",\n        \"SLC14A1\",\n        \"KCNN3\",\n        \"ATP1A2\",\n        \"SCN7A\",\n        \"TTYH1\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"AQP5\",\n          \"NKCC1\",\n          \"NHE1\",\n          \"AE2\",\n          \"ENaC\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"1\",\n            \"notes\": \"AQP5 expressed in some glioma patient biopsies\"\n          },\n          {\n            \"source_id\": \"25\",\n            \"notes\": \"NKCC, NHE1, and AE2 are critical for RVI and migration\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Extracellular Matrix Proteolysis and Invasiveness\",\n      \"description\": \"Coordinated expression of proteases (serine proteases, metalloproteinases, transmembrane proteases) and protease inhibitors that remodel the neural extracellular matrix. This program enables glioma cells to degrade neural ECM components (aggrecan, brevican, hyaluronic acid) and replace them with mesenchymal matrix proteins (fibronectin, collagens), switching from an inhibitory to a permissive microenvironment for cell migration and dissemination.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Serine and metalloproteinase activity\",\n          \"citations\": [\n            {\n              \"source_id\": \"13\",\n              \"notes\": \"SERPINA3 expressed in glioma-astrocyte interactions promotes ECM invasion\"\n            },\n            {\n              \"source_id\": \"16\",\n              \"notes\": \"uPA, cathepsin B, and MMPs upregulated in glioma; critical for ECM degradation\"\n            },\n            {\n              \"source_id\": \"27\",\n              \"notes\": \"CFI (complement factor I) regulates protease activity; overexpressed in glioma\"\n            }\n          ],\n          \"genes\": [\n            \"SERPINA3\",\n            \"CFI\",\n            \"ADAMTS8\",\n            \"ADAMTS15\",\n            \"MASP1\"\n          ]\n        },\n        {\n          \"name\": \"Proteoglycan and hyaluronic acid remodeling\",\n          \"citations\": [\n            {\n              \"source_id\": \"20\",\n              \"notes\": \"HAS2 upregulation promotes hyaluronic acid secretion and chemoresistance\"\n            },\n            {\n              \"source_id\": \"23\",\n              \"notes\": \"HAS3 expression correlates with glioma progression; modulates autophagy and proliferation\"\n            },\n            {\n              \"source_id\": \"38\",\n              \"notes\": \"Brevican (BCAN) cleaved by proteases interacts with fibronectin to promote motility\"\n            }\n          ],\n          \"genes\": [\n            \"HAS2\",\n            \"BCAN\",\n            \"FBLN5\",\n            \"TIMP3\"\n          ]\n        },\n        {\n          \"name\": \"Cell-ECM adhesion and integrin signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"21\",\n              \"notes\": \"ITGB4 mediates NTN4 effects on glioma proliferation via PI3K-AKT-mTOR\"\n            },\n            {\n              \"source_id\": \"24\",\n              \"notes\": \"ITGB4 upregulation predicts poor prognosis in lower-grade glioma; correlates with immune infiltration\"\n            },\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"CD44 high expression in GSCs promotes invasion and mediates HA binding\"\n            }\n          ],\n          \"genes\": [\n            \"ITGB4\",\n            \"CD44\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Extracellular matrix components\",\n          \"citations\": [\n            {\n              \"source_id\": \"16\",\n              \"notes\": \"ECM proteins including hyaluronic acid, proteoglycans, fibronectin, collagen critical for invasion\"\n            },\n            {\n              \"source_id\": \"38\",\n              \"notes\": \"Brevican secreted and cleaved by glioma cells; interacts with fibronectin\"\n            },\n            {\n              \"source_id\": \"41\",\n              \"notes\": \"Proteoglycan brevican binds fibronectin after cleavage to promote motility\"\n            }\n          ],\n          \"genes\": [\n            \"BCAN\",\n            \"HAS2\",\n            \"FBLN5\",\n            \"COL28A1\",\n            \"F3\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced degradation of inhibitory neural ECM components\",\n        \"Secretion of mesenchymal ECM proteins promoting adhesion and motility\",\n        \"Increased matrix metalloproteinase activity through positive feedback loops\",\n        \"Altered cell-ECM interactions promoting invasion-permissive phenotype\",\n        \"Resistance to chemotherapy through ECM-mediated signaling\"\n      ],\n      \"evidence_summary\": \"SERPINA3 is significantly upregulated in glioma and promotes invasion through ECM remodeling. ADAMTS proteases, HAS2, and other proteases work coordinately to remodel the ECM. Brevican, secreted and cleaved by glioma cells, interacts with fibronectin to enhance cell adhesion and motility. ITGB4 expression correlates with glioma grade and predicts poor survival. CD44 serves as a receptor for hyaluronic acid and promotes both invasion and proliferation. The balance between protease activity (ADAMTS, SERPINA3) and inhibitor expression (TIMP3) determines the extent of ECM remodeling and invasiveness.\",\n      \"significance_score\": 0.88,\n      \"citations\": [\n        {\n          \"source_id\": \"13\",\n          \"notes\": \"SERPINA3 promotes glioma invasion in ECM\"\n        },\n        {\n          \"source_id\": \"16\",\n          \"notes\": \"Comprehensive review of proteases in GBM invasion\"\n        },\n        {\n          \"source_id\": \"20\",\n          \"notes\": \"HAS2 promotes glioma proliferation, invasion, and chemoresistance\"\n        },\n        {\n          \"source_id\": \"38\",\n          \"notes\": \"Brevican-fibronectin interaction promotes glioma motility\"\n        },\n        {\n          \"source_id\": \"24\",\n          \"notes\": \"ITGB4 upregulation in glioma associated with poor prognosis\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"SERPINA3\",\n        \"ADAMTS8\",\n        \"ADAMTS15\",\n        \"HAS2\",\n        \"BCAN\",\n        \"FBLN5\",\n        \"TIMP3\",\n        \"ITGB4\",\n        \"CD44\",\n        \"CFI\",\n        \"MASP1\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"MMP2\",\n          \"MMP9\",\n          \"uPA\",\n          \"uPAR\",\n          \"Cathepsin B\",\n          \"RECK\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"16\",\n            \"notes\": \"MMP2, MMP9, uPA, and cathepsin B are key proteases in GBM invasion\"\n          },\n          {\n            \"source_id\": \"47\",\n            \"notes\": \"MMP-9 upregulated by EGF/EGFR signaling in GBM metastasis\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Glioma Stem Cell Identity and State Plasticity\",\n      \"description\": \"Regulatory network controlling differentiation, stemness markers, and phenotypic plasticity in glioma stem-like cells (GSCs). This program includes transcription factors that suppress differentiation (ID3, ID4, HOPX), stemness markers (CD44, CD38), glial differentiation markers (GFAP, ALDH1L1), and signaling pathways that maintain GSC self-renewal while permitting transitions to proneural, neural progenitor, and mesenchymal states depending on microenvironmental cues.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Inhibition of differentiation and stemness maintenance\",\n          \"citations\": [\n            {\n              \"source_id\": \"2\",\n              \"notes\": \"GFAPδ/α ratio increased in high-grade gliomas; higher ratio associated with stemness and malignancy\"\n            },\n            {\n              \"source_id\": \"19\",\n              \"notes\": \"Id4 suppresses MMP2 and glioma invasion; inversely correlates with MMP2 expression\"\n            },\n            {\n              \"source_id\": \"22\",\n              \"notes\": \"Id proteins (Id1, Id2, Id3) downregulated during differentiation\"\n            },\n            {\n              \"source_id\": \"39\",\n              \"notes\": \"HOPX regulates differentiation and proliferation states in glioblastoma\"\n            }\n          ],\n          \"genes\": [\n            \"ID3\",\n            \"ID4\",\n            \"HOPX\"\n          ]\n        },\n        {\n          \"name\": \"Stemness and cancer stem cell markers\",\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"CD44 high expression in GSCs; required for invasion and tumorigenicity\"\n            },\n            {\n              \"source_id\": \"6\",\n              \"notes\": \"CD44 expressed in mesenchymal-like GSCs; associated with poor prognosis\"\n            },\n            {\n              \"source_id\": \"8\",\n              \"notes\": \"CD38 expressed on immune cells and tumor cells; regulatory role in glioma progression\"\n            },\n            {\n              \"source_id\": \"11\",\n              \"notes\": \"CD38 targeted with daratumumab causes enhanced cell death in GBM\"\n            }\n          ],\n          \"genes\": [\n            \"CD44\",\n            \"CD38\"\n          ]\n        },\n        {\n          \"name\": \"Astrocyte differentiation markers\",\n          \"citations\": [\n            {\n              \"source_id\": \"2\",\n              \"notes\": \"GFAP isoforms distinguish differentiation states; GFAPα downregulated in high-grade gliomas\"\n            },\n            {\n              \"source_id\": \"5\",\n              \"notes\": \"GFAP used to determine glial differentiation state in astrocytoma\"\n            },\n            {\n              \"source_id\": \"55\",\n              \"notes\": \"ALDH1L1 underexpressed in aggressive gliomas; marks reactive astrocytes\"\n            }\n          ],\n          \"genes\": [\n            \"GFAP\",\n            \"ALDH1L1\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Cell surface markers and receptors\",\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"CD44 serves as hyaluronic acid receptor on GSCs\"\n            },\n            {\n              \"source_id\": \"6\",\n              \"notes\": \"CD24, CD133, EGFR, CD44 distinguish GSC cellular states\"\n            }\n          ],\n          \"genes\": [\n            \"CD44\",\n            \"CD38\",\n            \"GFAP\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Maintenance of undifferentiated, self-renewing GSC state\",\n        \"Reduced commitment to terminal astrocyte differentiation\",\n        \"Enhanced tumorigenicity and therapy resistance\",\n        \"Preserved capacity for phenotypic plasticity in response to microenvironmental signals\",\n        \"Increased resistance to differentiation-inducing therapies\"\n      ],\n      \"evidence_summary\": \"ID proteins (ID3, ID4) suppress differentiation and maintain stemness in glioma cells. HOPX regulates the balance between differentiation and proliferation, with knockout leading to mesenchymal transition. CD44 is highly expressed in GSCs and promotes both invasion and stemness. CD38 serves as an immune marker correlating with malignancy. GFAP isoforms (GFAPα vs GFAPδ) distinguish differentiation states, with GFAPδ overexpression indicating stemness and poor prognosis. ALDH1L1 underexpression in aggressive gliomas suggests loss of differentiated astrocyte identity. Together, these genes establish a program that suppresses differentiation while maintaining self-renewal capacity.\",\n      \"significance_score\": 0.85,\n      \"citations\": [\n        {\n          \"source_id\": \"2\",\n          \"notes\": \"GFAPδ as biomarker and therapeutic target in glioblastoma\"\n        },\n        {\n          \"source_id\": \"3\",\n          \"notes\": \"CD44 role in glioblastoma invasion and stem cell properties\"\n        },\n        {\n          \"source_id\": \"19\",\n          \"notes\": \"Id4 suppresses invasion and correlates with survival\"\n        },\n        {\n          \"source_id\": \"39\",\n          \"notes\": \"HOPX regulates differentiation in glioblastoma\"\n        },\n        {\n          \"source_id\": \"55\",\n          \"notes\": \"ALDH1L1 underexpression in aggressive astrocytomas\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"ID3\",\n        \"ID4\",\n        \"HOPX\",\n        \"CD44\",\n        \"CD38\",\n        \"GFAP\",\n        \"ALDH1L1\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"SOX2\",\n          \"OCT4\",\n          \"NANOG\",\n          \"CD133\",\n          \"CD24\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"6\",\n            \"notes\": \"SOX2, OCT4, CD133, CD24, EGFR define GSC states\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Endothelin Signaling and Proneural-Mesenchymal Transition\",\n      \"description\": \"G-protein-coupled receptor (GPCR) signaling through endothelin receptors (EDNRA, EDNRB) that regulates phenotypic plasticity between proneural and mesenchymal states. EDNRB is predominantly expressed in astrocyte-like cells and suppresses proliferation while promoting migration and mesenchymal transition. EDNRA expression is restricted to perivascular populations. This signaling integrates with calcium-dependent pathways (KCNN3) and transcriptional regulators to modulate cell fate decisions in response to oxygenation and cytokine gradients.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Endothelin receptor signaling and G-protein coupling\",\n          \"citations\": [\n            {\n              \"source_id\": \"15\",\n              \"notes\": \"EDNRB predominant receptor in glioma; EDNRA in perivascular subset; endothelin reduces proliferation while promoting migration and PMT\"\n            },\n            {\n              \"source_id\": \"18\",\n              \"notes\": \"Autocrine EDN3/EDNRB signaling maintains GSC; blocking induces apoptosis\"\n            }\n          ],\n          \"genes\": [\n            \"EDNRA\",\n            \"EDNRB\"\n          ]\n        },\n        {\n          \"name\": \"Calcium and potassium channel activation downstream of EDNRB\",\n          \"citations\": [\n            {\n              \"source_id\": \"15\",\n              \"notes\": \"EDNRB activation increases intracellular Ca2+ and activates ERK, STAT3, and SK2/SK3 potassium channels\"\n            },\n            {\n              \"source_id\": \"26\",\n              \"notes\": \"Calcium-activated potassium channels mediate glioma migration and invasiveness\"\n            }\n          ],\n          \"genes\": [\n            \"KCNN3\"\n          ]\n        },\n        {\n          \"name\": \"Proneural to mesenchymal transition (PMT)\",\n          \"citations\": [\n            {\n              \"source_id\": \"15\",\n              \"notes\": \"Endothelin signaling promotes migration and PMT while reducing proliferation\"\n            },\n            {\n              \"source_id\": \"14\",\n              \"notes\": \"ADAM15 overexpression enhances EMT markers via PAR1/EMT pathway in glioblastoma\"\n            }\n          ],\n          \"genes\": [\n            \"EDNRA\",\n            \"EDNRB\",\n            \"ADAMTS8\",\n            \"ADAMTS15\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"G-protein-coupled receptor signaling complex\",\n          \"citations\": [\n            {\n              \"source_id\": \"15\",\n              \"notes\": \"EDNRB is predominant GPCR in glioma cells; upregulated by BMPs, downregulated by interferons and IL-6\"\n            }\n          ],\n          \"genes\": [\n            \"EDNRA\",\n            \"EDNRB\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Regulated transition between proliferative proneural and invasive mesenchymal states\",\n        \"Suppression of proliferation coupled with enhanced migration capacity\",\n        \"Calcium signaling activation promoting cellular plasticity\",\n        \"Context-dependent phenotype determined by oxygen tension and cytokine gradients\",\n        \"Maintained GSC characteristics through autocrine endothelin signaling\"\n      ],\n      \"evidence_summary\": \"EDNRB is the predominant endothelin receptor in glioma cells, enriched in astrocyte-like populations. Endothelin signaling reduces proliferation while promoting migration and mesenchymal transition across all glioma models tested. EDNRA is expressed in a perivascular subset and induced by Notch signaling and hypoxia. The program integrates with calcium signaling (via KCNN3) to activate downstream effectors including ERK, STAT3, and potassium channels. This dual regulation allows glioma cells to suppress proliferation under certain microenvironmental conditions while maintaining migratory capacity, a pattern consistent with invasive tumor biology.\",\n      \"significance_score\": 0.78,\n      \"citations\": [\n        {\n          \"source_id\": \"15\",\n          \"notes\": \"Endothelin signaling via EDNRB reduces proliferation, promotes migration and PMT\"\n        },\n        {\n          \"source_id\": \"18\",\n          \"notes\": \"Autocrine EDN3/EDNRB signaling maintains GSC self-renewal\"\n        },\n        {\n          \"source_id\": \"14\",\n          \"notes\": \"ADAM15 and PAR1 modulate EMT in glioblastoma\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"EDNRA\",\n        \"EDNRB\",\n        \"KCNN3\",\n        \"ADAMTS8\",\n        \"ADAMTS15\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"EDN1\",\n          \"EDN2\",\n          \"EDN3\",\n          \"BMP ligands\",\n          \"Notch signaling components\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"15\",\n            \"notes\": \"Endothelin ligands EDN1-3 regulate receptor signaling; BMPs upregulate EDNRB\"\n          },\n          {\n            \"source_id\": \"18\",\n            \"notes\": \"EDN3 produced in autocrine manner; EDN1 elevated in tumors\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Glycolytic Metabolism and Warburg Effect\",\n      \"description\": \"Metabolic reprogramming toward aerobic glycolysis to support rapid proliferation and survival. This program includes rate-limiting glycolytic enzymes (PFKFB3), upstream regulators of glycolytic flux, and cofactors involved in one-carbon metabolism and nucleotide biosynthesis (ALDH1L1). The program also coordinates with hypoxic signaling and glucose availability sensing to shift metabolism from oxidative phosphorylation to glucose-dependent glycolysis.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Glycolytic pathway acceleration\",\n          \"citations\": [\n            {\n              \"source_id\": \"50\",\n              \"notes\": \"PFKFB3 splice variants regulate glycolytic flux; PFKFB3-4 overexpression increases viability and proliferation\"\n            },\n            {\n              \"source_id\": \"53\",\n              \"notes\": \"PFKFB3-4 to PFKFB3-5 ratio shifted toward PFKFB3-4 in IDH-wildtype glioblastomas\"\n            },\n            {\n              \"source_id\": \"51\",\n              \"notes\": \"PI3K/Akt pathway regulates glucose metabolism; Akt activation renders cells glucose-dependent\"\n            }\n          ],\n          \"genes\": [\n            \"PFKFB3\"\n          ]\n        },\n        {\n          \"name\": \"One-carbon metabolism and nucleotide synthesis\",\n          \"citations\": [\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"RA metabolism genes including ALDH enzymes regulate glioma progression\"\n            },\n            {\n              \"source_id\": \"55\",\n              \"notes\": \"ALDH1L1 involved in folate metabolism; underexpressed in aggressive gliomas\"\n            }\n          ],\n          \"genes\": [\n            \"ALDH1L1\"\n          ]\n        },\n        {\n          \"name\": \"Hyaluronic acid synthesis and accumulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"20\",\n              \"notes\": \"HAS2 upregulation promotes glioma proliferation through c-myc pathway\"\n            },\n            {\n              \"source_id\": \"23\",\n              \"notes\": \"HAS3 inhibition blocks autophagy flux and arrests cell cycle in G1\"\n            }\n          ],\n          \"genes\": [\n            \"HAS2\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Glycolytic enzyme complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"50\",\n              \"notes\": \"PFKFB3 regulates fructose-2,6-bisphosphate production and allosteric activation of 6-phosphofructo-1-kinase\"\n            }\n          ],\n          \"genes\": [\n            \"PFKFB3\"\n          ]\n        },\n        {\n          \"name\": \"Mitochondrial and cytosolic metabolic enzymes\",\n          \"citations\": [\n            {\n              \"source_id\": \"55\",\n              \"notes\": \"ALDH1L1 functions as cytosolic dehydrogenase in folate metabolism\"\n            }\n          ],\n          \"genes\": [\n            \"ALDH1L1\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced glycolytic flux supporting rapid ATP and biosynthetic precursor production\",\n        \"Increased glucose-dependent survival with enhanced sensitivity to glucose withdrawal\",\n        \"Accumulation of hyaluronic acid supporting ECM remodeling and chemoresistance\",\n        \"Balanced nucleotide synthesis supporting rapid proliferation\",\n        \"Metabolic flexibility through splice variant-specific PFKFB3 effects\"\n      ],\n      \"evidence_summary\": \"PFKFB3 is significantly overexpressed in glioblastoma with a marked shift toward PFKFB3-4 splice variants that enhance kinase activity and promote proliferation. Overexpression of PFKFB3-4 (but not PFKFB3-5) increases cell viability and proliferation, indicating splice variant-specific functional differences. HAS2 upregulation promotes proliferation and chemoresistance through the c-myc pathway. ALDH1L1, involved in folate metabolism and one-carbon unit generation, is underexpressed in aggressive gliomas, suggesting altered nucleotide biosynthesis capacity. Together these genes establish the metabolic landscape characteristic of the Warburg effect in glioblastoma.\",\n      \"significance_score\": 0.72,\n      \"citations\": [\n        {\n          \"source_id\": \"50\",\n          \"notes\": \"PFKFB3 splice variants in glioblastomas; functional diversity\"\n        },\n        {\n          \"source_id\": \"20\",\n          \"notes\": \"HAS2 promotes glioma proliferation and chemoresistance\"\n        },\n        {\n          \"source_id\": \"55\",\n          \"notes\": \"ALDH1L1 underexpression in aggressive astrocytomas\"\n        },\n        {\n          \"source_id\": \"51\",\n          \"notes\": \"PI3K signaling couples glucose metabolism to proliferation\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"PFKFB3\",\n        \"HAS2\",\n        \"ALDH1L1\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"HIF1α\",\n          \"c-myc\",\n          \"MTHFD1\",\n          \"MTHFR\",\n          \"PKM2\",\n          \"LDHA\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"20\",\n            \"notes\": \"HIF1α regulates HAS2 expression\"\n          },\n          {\n            \"source_id\": \"31\",\n            \"notes\": \"Multiple RA metabolism genes and metabolic pathways involved\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Complement Cascade Activation and Immune Evasion\",\n      \"description\": \"Dysregulation of the complement system to promote tumor growth, immune evasion, and therapy resistance. This program includes components of the complement cascade (C3, CFI, MASP1, COLEC12) that shift from immune surveillance toward pro-tumoral immune signaling. Complement activation in the tumor microenvironment promotes myeloid cell recruitment, T cell exhaustion, and immunosuppression while providing survival and proliferative signals to tumor cells.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Complement cascade activation and regulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"27\",\n              \"notes\": \"CFI is complement factor that inactivates cascade; overexpressed in glioma predicts poor prognosis\"\n            },\n            {\n              \"source_id\": \"57\",\n              \"notes\": \"C3/C3a/C3aR promotes tumor growth, metastasis, EMT, and angiogenesis\"\n            },\n            {\n              \"source_id\": \"60\",\n              \"notes\": \"C3a/C3aR upregulated in glioblastoma; associated with poor prognosis\"\n            }\n          ],\n          \"genes\": [\n            \"C3\",\n            \"CFI\",\n            \"MASP1\",\n            \"COLEC12\"\n          ]\n        },\n        {\n          \"name\": \"Immune cell recruitment and polarization\",\n          \"citations\": [\n            {\n              \"source_id\": \"8\",\n              \"notes\": \"CD38 suppresses CD8+ T cells; primary resistance mechanism to PD-1/PD-L1 blockade\"\n            },\n            {\n              \"source_id\": \"43\",\n              \"notes\": \"CHI3L2 expressed in tumor cells and macrophages; correlates with immune infiltration\"\n            },\n            {\n              \"source_id\": \"57\",\n              \"notes\": \"C3a promotes macrophage polarization and T cell exhaustion\"\n            }\n          ],\n          \"genes\": [\n            \"CD38\",\n            \"CHI3L2\",\n            \"CD44\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Complement protein complexes and receptors\",\n          \"citations\": [\n            {\n              \"source_id\": \"57\",\n              \"notes\": \"C3aR and C5aR present on various immune cells and tumor cells\"\n            },\n            {\n              \"source_id\": \"60\",\n              \"notes\": \"Complement components C1q, C3, C4, C5, MAC, C3aR, C5aR expressed in neurons and immune cells\"\n            }\n          ],\n          \"genes\": [\n            \"C3\",\n            \"CFI\",\n            \"MASP1\",\n            \"COLEC12\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Sustained complement activation promoting pro-tumoral inflammation\",\n        \"Recruitment and polarization of tumor-associated macrophages toward M2 phenotype\",\n        \"Suppression of anti-tumor CD8+ T cell responses\",\n        \"Enhanced tumor cell survival and proliferation through C3a/C3aR signaling\",\n        \"Angiogenic response promoting tumor vascularization\",\n        \"Resistance to conventional immunotherapies\"\n      ],\n      \"evidence_summary\": \"CFI is significantly overexpressed in gliomas and functions as an independent prognostic factor. High CFI expression correlates with worse overall survival and progression-free survival. C3 and CFI are upregulated in glioblastoma tissues and associated with poor prognosis. C3a/C3aR signaling promotes tumor growth, metastasis, and EMT while recruiting and polarizing macrophages toward immunosuppressive phenotypes. CD38 suppresses CD8+ T cells and represents a primary mechanism of resistance to PD-1/PD-L1 checkpoint inhibitors. CHI3L2 is expressed in both tumor cells and macrophages and correlates with immune infiltration markers including M1/M2 macrophages and T cell exhaustion. Together, these genes establish a program that corrupts the complement system from an immune surveillance mechanism into a tumor-promoting mechanism.\",\n      \"significance_score\": 0.75,\n      \"citations\": [\n        {\n          \"source_id\": \"27\",\n          \"notes\": \"CFI overexpression associated with poor prognosis in glioma\"\n        },\n        {\n          \"source_id\": \"30\",\n          \"notes\": \"CFI as independent prognostic factor in glioma\"\n        },\n        {\n          \"source_id\": \"57\",\n          \"notes\": \"Complement targeting in malignant glioma\"\n        },\n        {\n          \"source_id\": \"8\",\n          \"notes\": \"CD38 and glioblastoma immune evasion\"\n        },\n        {\n          \"source_id\": \"60\",\n          \"notes\": \"Complement cascades and brain disorders including glioblastoma\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"C3\",\n        \"CFI\",\n        \"MASP1\",\n        \"COLEC12\",\n        \"CD38\",\n        \"CHI3L2\",\n        \"CD44\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"C1q\",\n          \"C4\",\n          \"C5\",\n          \"Factor B\",\n          \"Factor D\",\n          \"C3aR\",\n          \"C5aR\",\n          \"C5b-9\",\n          \"MAC\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"57\",\n            \"notes\": \"Complete complement cascade includes multiple components beyond C3 and CFI\"\n          },\n          {\n            \"source_id\": \"60\",\n            \"notes\": \"All three complement activation pathways active in glioblastoma\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Cell Polarity and Junctional Adhesion\",\n      \"description\": \"Establishment and maintenance of cell polarity complex proteins that regulate epithelial-like cell surface organization and cell-cell contacts through gap junctions and tight junction components. This program includes Crumbs polarity complex components (CRB2, MARVELD3) and connexins (GJA1) that mediate both cell-cell communication and regulation of paracrine signaling within the tumor microenvironment. Loss or redistribution of these proteins contributes to epithelial-to-mesenchymal transition and altered tumor-stromal communication.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Crumbs complex-mediated apical domain organization\",\n          \"citations\": [\n            {\n              \"source_id\": \"56\",\n              \"notes\": \"CRB2 involved in establishing cell polarity; located in neurons and presynaptic terminals\"\n            },\n            {\n              \"source_id\": \"59\",\n              \"notes\": \"CRB2 enhances malignancy via NF-κB pathway activation\"\n            }\n          ],\n          \"genes\": [\n            \"CRB2\",\n            \"MARVELD3\"\n          ]\n        },\n        {\n          \"name\": \"Gap junction-mediated intercellular communication\",\n          \"citations\": [\n            {\n              \"source_id\": \"37\",\n              \"notes\": \"Cx43 (GJA1) expressed in GBM; forms functional junctions with astrocytes; promotes invasion at tumor border\"\n            },\n            {\n              \"source_id\": \"40\",\n              \"notes\": \"Cx43 understood to be both tumor-suppressive and oncogenic depending on cancer stage\"\n            }\n          ],\n          \"genes\": [\n            \"GJA1\"\n          ]\n        },\n        {\n          \"name\": \"miRNA transfer and post-transcriptional regulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"37\",\n              \"notes\": \"Cx43-dependent transfer of miR-19b from GBM to astrocytes promotes invasion-permissive phenotype\"\n            }\n          ],\n          \"genes\": [\n            \"GJA1\",\n            \"ZFP36\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Polarity protein complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"56\",\n              \"notes\": \"CRB2 colocalizes with Pals1, a Crumbs complex member\"\n            }\n          ],\n          \"genes\": [\n            \"CRB2\",\n            \"MARVELD3\"\n          ]\n        },\n        {\n          \"name\": \"Gap junction channels\",\n          \"citations\": [\n            {\n              \"source_id\": \"37\",\n              \"notes\": \"GJA1 (Cx43) forms plaques with both GBM cells and astrocytes\"\n            }\n          ],\n          \"genes\": [\n            \"GJA1\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Altered cell polarity promoting loss of epithelial characteristics\",\n        \"Enhanced GBM-astrocyte communication through functional gap junctions\",\n        \"Transfer of pro-invasive miRNAs from tumor to stromal cells\",\n        \"Increased invasiveness at tumor-brain interface through miRNA-mediated remodeling of astrocyte adhesion\",\n        \"Context-dependent tumor-suppressive vs tumor-promoting effects depending on localization\"\n      ],\n      \"evidence_summary\": \"GJA1 (Cx43) is expressed in a subset of glioblastoma cells and forms functional gap junctions both between tumor cells and with neighboring astrocytes. Cx43 localizes to the tumor border where it drives invasion through transfer of miR-19b from GBM to astrocytes, promoting a pro-invasive peritumoral niche. Cx43 expression decreases with increasing astrocytoma grade, and Cx43-dependent communication is a major contributor to invasion. CRB2 is involved in establishing cell polarity and its overexpression enhances glioblastoma malignancy through NF-κB pathway activation. MARVELD3 participates in tight junction organization. Together these genes establish a polarity program that is partially retained in glioblastoma, with redistribution to tumor edges and conversion to pro-invasive signaling.\",\n      \"significance_score\": 0.68,\n      \"citations\": [\n        {\n          \"source_id\": \"37\",\n          \"notes\": \"Glioblastoma-astrocyte Cx43 gap junctions promote invasion\"\n        },\n        {\n          \"source_id\": \"40\",\n          \"notes\": \"Cx43 dual roles as tumor suppressor and oncogene\"\n        },\n        {\n          \"source_id\": \"56\",\n          \"notes\": \"CRB2 expression in normal brain and involvement in polarity\"\n        },\n        {\n          \"source_id\": \"59\",\n          \"notes\": \"CRB2 enhances malignancy via NF-κB pathway\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"GJA1\",\n        \"CRB2\",\n        \"MARVELD3\",\n        \"ZFP36\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"Pals1\",\n          \"PATJ\",\n          \"Rab8A\",\n          \"VPS35\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"56\",\n            \"notes\": \"CRB2 interacts with Pals1 and colocalizes with Rab8A and VPS35 in exocytic pathway\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Renin-Angiotensin System and Vascular Signaling\",\n      \"description\": \"Local renin-angiotensin system (RAS) expression and function in glioblastoma, including synthesis of angiotensinogen (AGT), renin, and angiotensin peptides. This program regulates tumor vascularity, angiogenesis, and may influence tumor cell survival through receptor-mediated signaling. While systemic RAS inhibitors have shown modest effects, selective renin inhibitors reduce GBM cell proliferation and survival independent of angiotensin peptide production.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Renin and angiotensinogen synthesis and processing\",\n          \"citations\": [\n            {\n              \"source_id\": \"32\",\n              \"notes\": \"Human glioblastoma produces renin and AGT; renin is rate-limiting for RAS and reduces proliferation when inhibited\"\n            }\n          ],\n          \"genes\": [\n            \"AGT\"\n          ]\n        },\n        {\n          \"name\": \"Renin-mediated proteolysis independent of angiotensin signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"32\",\n              \"notes\": \"Renin inhibition decreases DNA synthesis and viable tumor cell number; effect not counterbalanced by Ang II addition\"\n            }\n          ],\n          \"genes\": [\n            \"AGT\"\n          ]\n        },\n        {\n          \"name\": \"Angiotensin peptide receptor signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"32\",\n              \"notes\": \"GBM expresses renin, AGT, renin receptor, AT1 and AT2; expression varies between tumors\"\n          ],\n          \"genes\": [\n            \"AGT\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Renin-angiotensin protease complex\",\n          \"citations\": [\n            {\n              \"source_id\": \"32\",\n              \"notes\": \"Complete RAS expressed in glioblastoma; heterogeneous expression across tumor samples\"\n            }\n          ],\n          \"genes\": [\n            \"AGT\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Direct anti-proliferative effects of renin independent of angiotensin signaling\",\n        \"Potential regulation of tumor-associated angiogenesis through angiotensin-mediated vascular effects\",\n        \"Heterogeneous RAS expression between tumors potentially affecting therapy response\",\n        \"Resistance to ACE inhibitors but sensitivity to selective renin inhibitors\"\n      ],\n      \"evidence_summary\": \"Human glioblastoma cells produce and express components of the complete renin-angiotensin system, including renin, AGT, and both AT1 and AT2 receptors. However, angiotensin peptides do not directly modulate GBM cell growth, survival, or apoptosis. Instead, renin itself exerts anti-proliferative effects through mechanisms independent of angiotensin receptor signaling. Selective renin inhibitors decrease DNA synthesis, reduce viable tumor cell number, and induce apoptosis in GBM cells, an effect not reversed by exogenous angiotensin II. This suggests that the rate-limiting enzyme renin, rather than its peptide products, is the critical therapeutic target in the GBM RAS.\",\n      \"significance_score\": 0.55,\n      \"citations\": [\n        {\n          \"source_id\": \"32\",\n          \"notes\": \"Renin and angiotensinogen expression in glioblastoma; renin-mediated proliferation control\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"AGT\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"Renin\",\n          \"AT1 receptor\",\n          \"AT2 receptor\",\n          \"ACE\",\n          \"Angiotensinogen peptides\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"32\",\n            \"notes\": \"Multiple RAS components expressed; heterogeneous across tumor samples\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Pericyte-Mediated Tumor Angiogenesis and Vascular Remodeling\",\n      \"description\": \"Pericyte recruitment and molecular reprogramming toward proliferative and pro-angiogenic phenotypes during early glioblastoma progression. This program involves PDGF receptor signaling (PDGFRB) in pericytes and endothelial cells, with dual localization showing regional enrichment at the tumor-brain interface and focal positioning at vascular branch points. Early pericyte functions promote angiogenesis; late functions promote tumor growth, representing stage-dependent effects critical for vascular remodeling.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Pericyte recruitment and localization\",\n          \"citations\": [\n            {\n              \"source_id\": \"33\",\n              \"notes\": \"Pericytes undergo dual spatial reorganization: enrichment at tumor-brain interface and focal positioning at vascular branch points\"\n            }\n          ],\n          \"genes\": [\n            \"PDGFRB\"\n          ]\n        },\n        {\n          \"name\": \"PDGF-mediated endothelial-mesenchymal transformation\",\n          \"citations\": [\n            {\n              \"source_id\": \"36\",\n              \"notes\": \"PDGF induces Endo-MT through NF-κB-mediated Snail expression; reduces VEGFR-2 expression\"\n            }\n          ],\n          \"genes\": [\n            \"PDGFRB\"\n          ]\n        },\n        {\n          \"name\": \"Stage-dependent angiogenic vs growth-promoting effects\",\n          \"citations\": [\n            {\n              \"source_id\": \"33\",\n              \"notes\": \"Early pericyte ablation inhibits GBM progression; late ablation promotes it\"\n            }\n          ],\n          \"genes\": [\n            \"PDGFRB\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Pericyte cell surface markers and receptors\",\n          \"citations\": [\n            {\n              \"source_id\": \"33\",\n              \"notes\": \"PDGFRB+ cells identified by anatomical localization and morphological characteristics; pericytes regulate GBM growth\"\n            }\n          ],\n          \"genes\": [\n            \"PDGFRB\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Increased angiogenic sprouting from existing vasculature during early tumor development\",\n        \"Vascular co-option followed by neovascularization transition\",\n        \"Endothelial cell reprogramming toward mesenchymal phenotype reducing VEGFR-2 expression\",\n        \"Stage-dependent therapeutic targeting opportunities\",\n        \"Enhanced anti-VEGF resistance through pericyte-mediated vascular support\"\n      ],\n      \"evidence_summary\": \"PDGFRB+ pericytes are aberrantly recruited to glioblastoma vasculature and undergo molecular reprogramming toward proliferative and pro-angiogenic phenotypes. During early GBM progression, pericyte ablation inhibits tumor growth; during late stages, ablation promotes growth, indicating stage-dependent functional roles. Pericytes exhibit dynamic spatial reorganization with pre-sprouting accumulation at the tumor-brain interface and positioning at vascular branch points. PDGF induces endothelial-mesenchymal transformation through NF-κB-mediated Snail expression, reducing VEGFR-2 and contributing to anti-angiogenic therapy resistance. Proteomics analysis reveals conserved cross-species alterations in pericytes suggesting therapeutic targeting opportunities.\",\n      \"significance_score\": 0.62,\n      \"citations\": [\n        {\n          \"source_id\": \"33\",\n          \"notes\": \"Pericytes in glioblastoma angiogenesis: in vivo tracking and molecular reprogramming\"\n        },\n        {\n          \"source_id\": \"36\",\n          \"notes\": \"PDGF-mediated endothelial-mesenchymal transformation and anti-VEGF resistance\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"PDGFRB\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"PDGF ligands\",\n          \"VEGFR-2\",\n          \"VEGFR-1\",\n          \"VEGFR-3\",\n          \"Snail\",\n          \"NF-κB\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"36\",\n            \"notes\": \"PDGF and VEGFR cross-talk in endothelial cell reprogramming\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Epigenetic and Transcriptional Heterogeneity\",\n      \"description\": \"Dysregulation of epigenetic modifiers and transcriptional regulators controlling glioma differentiation states and therapy resistance. This program encompasses HOX gene dysregulation (HOXA cluster involvement), transcription factors maintaining stemness (HOPX, ID family), and associated metabolic consequences. HOX genes are virtually absent in normal adult brain but aberrantly expressed in gliomas, correlating with chromosome 7 gain and worse prognosis.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"HOX gene dysregulation and proliferation control\",\n          \"citations\": [\n            {\n              \"source_id\": \"42\",\n              \"notes\": \"HOXA genes dysregulated in GBM; HOXA3 regulates glycolytic metabolism; HOXA5 drives aggressiveness\"\n            }\n          ],\n          \"genes\": []\n        },\n        {\n          \"name\": \"Transcription factor-mediated differentiation suppression\",\n          \"citations\": [\n            {\n              \"source_id\": \"39\",\n              \"notes\": \"HOPX regulates differentiation and proliferation states; knockout increases mesenchymal transition\"\n            }\n          ],\n          \"genes\": [\n            \"HOPX\"\n          ]\n        },\n        {\n          \"name\": \"Metabolic reprogramming through transcriptional regulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"42\",\n              \"notes\": \"HOXA3 influences glycolytic metabolism via KDM6A regulatory axis\"\n            }\n          ],\n          \"genes\": []\n        }\n      ],\n      \"atomic_cellular_components\": [],\n      \"predicted_cellular_impact\": [\n        \"Aberrant HOX expression driving proliferation and metabolic reprogramming\",\n        \"Dysregulated cell cycle and DNA repair through HOX-mediated transcription\",\n        \"Correlation with chromosome 7 gain indicating genetic instability\",\n        \"Enhanced radiotherapy resistance through HOXA-mediated mechanisms\",\n        \"Prognostic implications through HOXA9-WNT6 co-expression signatures\"\n      ],\n      \"evidence_summary\": \"HOX genes are virtually absent in normal adult brain but aberrantly expressed in glioblastoma, representing a major dysregulation signature. HOXA genes show particularly pronounced alterations. HOXA3 influences glycolytic metabolism and cell proliferation through a HOXA3-KDM6A regulatory axis. HOXA5 expression correlates with chromosome 7 amplification and drives tumor aggressiveness while promoting radiotherapy resistance. HOXA9 is an independent prognostic factor associated with poor survival and is regulated by PI3K signaling; its co-expression with WNT6 identifies a particularly poor-prognosis subgroup. HOPX regulates the balance between differentiation and proliferation; its downregulation promotes mesenchymal transition. Together these genes establish an epigenetic program that reprograms the transcriptional landscape characteristic of normal brain.\",\n      \"significance_score\": 0.65,\n      \"citations\": [\n        {\n          \"source_id\": \"42\",\n          \"notes\": \"HOX gene dysregulation in glioblastoma; prognostic and functional roles\"\n        },\n        {\n          \"source_id\": \"39\",\n          \"notes\": \"HOPX in tissue differentiation and glioblastoma progression\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"HOPX\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"HOXA3\",\n          \"HOXA5\",\n          \"HOXA9\",\n          \"HOXB\",\n          \"HOXC\",\n          \"HOXD\",\n          \"KDM6A\",\n          \"WNT6\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"42\",\n            \"notes\": \"All four HOX clusters dysregulated; HOXA most pronounced\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"EGF Receptor Signaling and Metastatic Cascade\",\n      \"description\": \"Aberrant epidermal growth factor (EGF) and EGFR signaling driving glioblastoma proliferation, migration, and invasion through multiple downstream effector pathways. EGF and EGFR are upregulated in GBM tumor regions and edema zones. Signaling proceeds through PI3K/AKT and ERK1/2 pathways to activate matrix metalloproteinase-9 (MMP-9) and drive EMT-related processes. EGFR amplification occurs in ~36-40% of GBMs, often with constitutively active EGFRvIII variant.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"EGF/EGFR ligand-receptor complex formation and transactivation\",\n          \"citations\": [\n            {\n              \"source_id\": \"44\",\n              \"notes\": \"EGFR amplified in 36-40% of GBMs; EGFRvIII variant more oncogenic than wildtype\"\n            },\n            {\n              \"source_id\": \"47\",\n              \"notes\": \"EGF mRNA and protein upregulated in GBM and edema zones; EGFR similarly induced\"\n            }\n          ],\n          \"genes\": [\n            \"EGF\"\n          ]\n        },\n        {\n          \"name\": \"Downstream signaling through PI3K/AKT and ERK1/2 pathways\",\n          \"citations\": [\n            {\n              \"source_id\": \"47\",\n              \"notes\": \"EGF induces MMP-9 via EGFR through PI3K/AKT and ERK1/2 mechanisms\"\n            },\n            {\n              \"source_id\": \"51\",\n              \"notes\": \"PI3K/Akt pathway central to proliferation, growth, survival, and migration\"\n            }\n          ],\n          \"genes\": [\n            \"EGF\"\n          ]\n        },\n        {\n          \"name\": \"Transcriptional regulation of EMT and invasion-related genes\",\n          \"citations\": [\n            {\n              \"source_id\": \"47\",\n              \"notes\": \"STAT3 and STAT5 mediate NF-κB activation downstream of EGF/EGFR signaling\"\n            }\n          ],\n          \"genes\": [\n            \"EGF\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"EGFR at plasma membrane and in vesicles\",\n          \"citations\": [\n            {\n              \"source_id\": \"44\",\n              \"notes\": \"EGFR protein overexpressed at cell membrane and in cytoplasm in GBM\"\n            }\n          ],\n          \"genes\": [\n            \"EGF\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced proliferation through sustained EGFR signaling\",\n        \"Increased migration and invasion via MMP-9 upregulation\",\n        \"Epithelial-mesenchymal transition program activation\",\n        \"Chemoresistance through survival pathway activation\",\n        \"Postoperative elevation of EGF correlating with edema formation\",\n        \"EGFR as therapeutic target with resistance mechanisms\"\n      ],\n      \"evidence_summary\": \"EGF and EGFR expression are substantially upregulated in GBM tissues and edema zones. EGF mRNA and protein are elevated in both tumor regions and surrounding brain, with postoperative CSF analysis showing marked reduction. EGFR protein is overexpressed at the cell membrane in the majority of GBMs, with EGFR gene amplification present in 36-40% of cases. The EGFRvIII constitutively active variant is more tumorigenic than wildtype EGFR. EGF-EGFR signaling drives MMP-9 upregulation and secretion through both PI3K/AKT-dependent and ERK1/2-dependent STAT3/STAT5 mechanisms. NF-κB is downstream of these pathways and transactivates the MMP-9 promoter. MMP-9 in turn facilitates migration, invasion, and metastasis of GBM cells. The EGF/EGFR axis remains a critical therapeutic target despite modest clinical success with current approaches.\",\n      \"significance_score\": 0.7,\n      \"citations\": [\n        {\n          \"source_id\": \"44\",\n          \"notes\": \"EGFR signal transduction and role in glioma\"\n        },\n        {\n          \"source_id\": \"47\",\n          \"notes\": \"EGF stimulates glioblastoma metastasis via MMP-9\"\n        },\n        {\n          \"source_id\": \"51\",\n          \"notes\": \"PI3K signaling in glioblastoma\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"EGF\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"EGFR\",\n          \"EGFRvIII\",\n          \"TGFα\",\n          \"HB-EGF\",\n          \"MMP-9\",\n          \"STAT3\",\n          \"STAT5\",\n          \"NF-κB\",\n          \"PI3K\",\n          \"AKT\",\n          \"ERK1/2\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"44\",\n            \"notes\": \"Complete EGFR signaling cascade requires multiple downstream effectors\"\n          },\n          {\n            \"source_id\": \"47\",\n            \"notes\": \"EGF-EGFR-MMP-9 axis central to metastasis\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Innate Immune Activation and Interferon Response\",\n      \"description\": \"Activation of RIG-I-like receptors (RLRs) including RIG-I and MDA5, triggering innate immune responses and direct glioma cell apoptosis. This emerging therapeutic strategy stimulates both innate and adaptive immune responses through type I interferon production and cytokine/chemokine secretion, countering tumor-mediated immunosuppression and targeting heterogeneous GSC populations.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"RIG-I and MDA5 receptor activation by dsRNA ligands\",\n          \"citations\": [\n            {\n              \"source_id\": \"49\",\n              \"notes\": \"RLRs activation by polyinosinic-polycytidylic acid and 3' triphosphate RNA induces innate immunity\"\n            },\n            {\n              \"source_id\": \"52\",\n              \"notes\": \"RIG-I and MDA5 activation targets different malignant glioma populations; effective against GSCs\"\n            }\n          ],\n          \"genes\": []\n        },\n        {\n          \"name\": \"Type I interferon production and antiviral response\",\n          \"citations\": [\n            {\n              \"source_id\": \"49\",\n              \"notes\": \"RLR activation produces type I IFN and CXCL10 in glioblastoma\"\n            },\n            {\n              \"source_id\": \"52\",\n              \"notes\": \"IFN-dependent and IFN-independent apoptosis induction in GSCs\"\n            }\n          ],\n          \"genes\": []\n        },\n        {\n          \"name\": \"Direct glioma cell apoptosis induction\",\n          \"citations\": [\n            {\n              \"source_id\": \"49\",\n              \"notes\": \"All investigated GBM populations respond to RLR stimulation with apoptotic signaling\"\n            },\n            {\n              \"source_id\": \"52\",\n              \"notes\": \"Pronounced apoptosis induction in stem cell-enriched and non-stem populations\"\n            }\n          ],\n          \"genes\": []\n        },\n        {\n          \"name\": \"Immune cell activation and recruitment\",\n          \"citations\": [\n            {\n              \"source_id\": \"49\",\n              \"notes\": \"RLR activation recruits and activates NK cells, macrophages, and cross-primes CD8+ T cells\"\n            },\n            {\n              \"source_id\": \"52\",\n              \"notes\": \"Reduced T-regulatory cell differentiation and increased CD8+ T lymphocyte recruitment\"\n            }\n          ],\n          \"genes\": []\n        }\n      ],\n      \"atomic_cellular_components\": [],\n      \"predicted_cellular_impact\": [\n        \"Direct apoptosis of diverse glioma populations including GSCs\",\n        \"Type I interferon production creating anti-tumor state\",\n        \"Recruitment and activation of cytotoxic NK cells and CD8+ T cells\",\n        \"Macrophage activation and polarization toward M1 phenotype\",\n        \"Enhanced tumor infiltration by anti-tumor immune cells\",\n        \"Potential overcoming of immunotherapy resistance\"\n      ],\n      \"evidence_summary\": \"RIG-I and MDA5 are cytosolic nucleic acid sensors activated by recognition of immunostimulatory RNAs. In glioblastoma, their activation with synthetic ligands (p(I:C) and 3pRNA) triggers innate immune responses and direct glioma cell apoptosis across all investigated populations, including stem cell-enriched and differentiated populations. Apoptosis is induced through both IFN-dependent and IFN-independent mechanisms. RLR activation produces type I interferons and chemokines (CXCL10) that recruit and activate innate immune effectors including NK cells and macrophages. CD8+ T cell recruitment is enhanced with reduced T-regulatory cell differentiation. Notably, RLR ligands induce minimal toxicity in non-malignant neural cells, suggesting selective targeting of tumor cells. This approach represents an emerging strategy to overcome tumor heterogeneity and immunosuppression.\",\n      \"significance_score\": 0.68,\n      \"citations\": [\n        {\n          \"source_id\": \"49\",\n          \"notes\": \"Harnessing RIG-I-like receptor activation to inhibit glioblastoma\"\n        },\n        {\n          \"source_id\": \"52\",\n          \"notes\": \"Targeting RIG-I and MDA5 counteracts glioblastoma cell heterogeneity\"\n        }\n      ],\n      \"supporting_genes\": [],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"RIG-I\",\n          \"MDA5\",\n          \"MAVS\",\n          \"IRF3\",\n          \"IRF7\",\n          \"IFN-β\",\n          \"CXCL10\",\n          \"TNF-α\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"49\",\n            \"notes\": \"Complete RLR pathway requires multiple downstream effectors\"\n          }\n        ]\n      }\n    }\n  ],\n  \"method\": {\n    \"clustering_basis\": [\n      \"pathway analysis\",\n      \"gene co-expression in glioblastoma\",\n      \"literature review and citation networks\",\n      \"known protein-protein interactions\",\n      \"functional genomics and phenotypic outcomes\"\n    ],\n    \"notes\": \"Gene programs were identified through systematic analysis of provided search results, focusing on well-established roles in glioblastoma biology. Programs group genes that function together in specific biological processes or cellular states. Gene list includes aquaporins, ion channels, ECM remodeling enzymes, stemness markers, transcription factors, metabolic enzymes, immune mediators, and signaling components. Analysis prioritized multiple genes acting in same pathway (enabling high significance scores) and identified required genes absent from input list to clarify pathway completeness. Several input genes (e.g., FAM189A2, AC092131.1, LRRC2, STUM, SPON1, HCG22, etc.) lack specific glioblastoma literature and were not assigned to programs.\"\n  },\n  \"version\": \"1.0\"\n}\n```\n\n## Citations\n\n1. https://pmc.ncbi.nlm.nih.gov/articles/PMC2561225/\n2. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.859247/full\n3. https://pmc.ncbi.nlm.nih.gov/articles/PMC10572085/\n4. https://www.oncotarget.com/article/16017/text/\n5. https://pmc.ncbi.nlm.nih.gov/articles/PMC6617972/\n6. https://www.nature.com/articles/s41467-025-58366-5\n7. https://pubmed.ncbi.nlm.nih.gov/40167966/\n8. https://pmc.ncbi.nlm.nih.gov/articles/PMC11660118/\n9. https://pmc.ncbi.nlm.nih.gov/articles/PMC11726635/\n10. https://pmc.ncbi.nlm.nih.gov/articles/PMC11803017/\n11. https://www.neurology.org/doi/10.1212/WNL.90.15_supplement.P4.160\n12. https://pmc.ncbi.nlm.nih.gov/articles/PMC11853410/\n13. https://pmc.ncbi.nlm.nih.gov/articles/PMC5769378/\n14. https://pmc.ncbi.nlm.nih.gov/articles/PMC12010881/\n15. https://sciety-labs.elifesciences.org/articles/by?article_doi=10.1101%2F2025.09.05.674570\n16. https://pmc.ncbi.nlm.nih.gov/articles/PMC6395056/\n17. https://core.ac.uk/download/pdf/225412782.pdf\n18. https://pmc.ncbi.nlm.nih.gov/articles/PMC3245317/\n19. https://pubmed.ncbi.nlm.nih.gov/24413082/\n20. https://pubmed.ncbi.nlm.nih.gov/38734194/\n21. https://pmc.ncbi.nlm.nih.gov/articles/PMC3323899/\n22. https://pubmed.ncbi.nlm.nih.gov/11756408/\n23. https://www.nature.com/articles/s41419-021-03747-z\n24. https://www.nature.com/articles/s41598-023-49801-y\n25. https://pmc.ncbi.nlm.nih.gov/articles/PMC6676112/\n26. https://pmc.ncbi.nlm.nih.gov/articles/PMC10144598/\n27. https://pmc.ncbi.nlm.nih.gov/articles/PMC7889977/\n28. https://tau.amegroups.org/article/view/87727/html\n29. https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0012304\n30. https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2020.615970/full\n31. https://pmc.ncbi.nlm.nih.gov/articles/PMC11479434/\n32. https://pmc.ncbi.nlm.nih.gov/articles/PMC2409624/\n33. https://pmc.ncbi.nlm.nih.gov/articles/PMC12531104/\n34. https://pmc.ncbi.nlm.nih.gov/articles/PMC3421472/\n35. https://febs.onlinelibrary.wiley.com/doi/10.1002/1878-0261.12660\n36. https://www.nature.com/articles/s41467-018-05982-z\n37. https://pmc.ncbi.nlm.nih.gov/articles/PMC8816813/\n38. https://pmc.ncbi.nlm.nih.gov/articles/PMC3259830/\n39. https://pmc.ncbi.nlm.nih.gov/articles/PMC12608687/\n40. https://www.nature.com/articles/s41419-025-07514-2\n41. https://www.nature.com/articles/s41698-025-00956-z\n42. https://pmc.ncbi.nlm.nih.gov/articles/PMC12092875/\n43. https://pmc.ncbi.nlm.nih.gov/articles/PMC8084183/\n44. https://pmc.ncbi.nlm.nih.gov/articles/PMC2933688/\n45. https://pmc.ncbi.nlm.nih.gov/articles/PMC3246703/\n46. https://www.nature.com/articles/s41598-024-77930-5\n47. https://www.oncotarget.com/article/19622/text/\n48. https://www.frontiersin.org/journals/neuroanatomy/articles/10.3389/fnana.2021.591726/full\n49. https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2021.710171/full\n50. https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0241092\n51. https://pmc.ncbi.nlm.nih.gov/articles/PMC3116122/\n52. https://pubmed.ncbi.nlm.nih.gov/23390110/\n53. https://pubmed.ncbi.nlm.nih.gov/34234350/\n54. https://pmc.ncbi.nlm.nih.gov/articles/PMC2614703/\n55. https://pmc.ncbi.nlm.nih.gov/articles/PMC2730602/\n56. https://www.nature.com/articles/s41598-018-30210-5\n57. https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2021.657472/full\n58. https://www.abcam.com/en-us/products/primary-antibodies/aldh1l1-antibody-astrocyte-marker-ab190298\n59. https://www.ncbi.nlm.nih.gov/gene/286204\n60. https://pmc.ncbi.nlm.nih.gov/articles/PMC12384664/",
    "citations": [],
    "duration_seconds": 226.84
  }
}